{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:04:56Z","timestamp":1777367096756,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T00:00:00Z","timestamp":1465862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s40265-016-0602-3","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T12:02:07Z","timestamp":1465905727000},"page":"1135-1145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Secukinumab: A Review in Psoriatic Arthritis"],"prefix":"10.1007","volume":"76","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,14]]},"reference":[{"issue":"11","key":"602_CR1","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nrrheum.2009.210","volume":"5","author":"AP Anandarajah","year":"2009","unstructured":"Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol. 2009;5(11):634\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"602_CR2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423\u201341.","journal-title":"Drugs."},{"issue":"Suppl 1","key":"602_CR3","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2010.140582","volume":"70","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(Suppl 1):i77\u201384.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"602_CR4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2133.2007.08148.x","volume":"157","author":"DH Ciocon","year":"2007","unstructured":"Ciocon DH, Kimball AB. Psoriasis and psoriatic arthritis: separate or one and the same? Br J Dermatol. 2007;157(5):850\u201360.","journal-title":"Br J Dermatol"},{"issue":"1","key":"602_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/rheumatology\/keu237","volume":"54","author":"D Huynh","year":"2015","unstructured":"Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology. 2015;54(1):20\u20138.","journal-title":"Rheumatology"},{"issue":"Suppl 2","key":"602_CR6","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"602_CR7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"602_CR8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371.","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"602_CR9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrrheum.2014.106","volume":"10","author":"I Olivieri","year":"2014","unstructured":"Olivieri I, D\u2019Angelo S, Palazzi C, et al. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10(9):531\u201342.","journal-title":"Nat Rev Rheumatol"},{"issue":"5 Suppl 93","key":"602_CR10","first-page":"S104","volume":"33","author":"P Mease","year":"2015","unstructured":"Mease P. A short history of biological therapy for psoriatic arthritis. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S104\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"602_CR11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","volume":"75","author":"S Ramiro","year":"2016","unstructured":"Ramiro S, Smolen JS, Landew\u00e9 R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2016;75(3):490\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"602_CR12","doi-asserted-by":"crossref","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","volume":"72","author":"DD Patel","year":"2013","unstructured":"Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii116\u201323.","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"602_CR13","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","volume":"58","author":"C Jandus","year":"2008","unstructured":"Jandus C, Bioley G, Rivals J-P, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58(8):2307\u201317.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"602_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133\u201342.","journal-title":"Immunology"},{"issue":"5","key":"602_CR15","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","volume":"15","author":"H Benham","year":"2013","unstructured":"Benham H, Norris P, Goodall J, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther. 2013;15(5):R136.","journal-title":"Arthritis Res Ther."},{"issue":"5","key":"602_CR16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","volume":"130","author":"S Kagami","year":"2010","unstructured":"Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373\u201383.","journal-title":"J Invest Dermatol."},{"issue":"5","key":"602_CR17","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","volume":"66","author":"B Menon","year":"2014","unstructured":"Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17\u00a0+\u00a0CD8\u00a0+\u00a0T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272\u201381.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 2","key":"602_CR18","doi-asserted-by":"crossref","first-page":"A79","DOI":"10.1136\/ard.2010.149013.27","volume":"70","author":"LGM Baarsen van","year":"2011","unstructured":"van Baarsen LGM, Lebre MC, van der Coelen D, et al. IL-17 levels in synovium of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis: target validation in various forms of arthritis [abstract no. A184]. Ann Rheum Dis. 2011;70(Suppl 2):A79.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"602_CR19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","volume":"16","author":"LGM Baarsen van","year":"2014","unstructured":"van Baarsen LGM, Lebre MC, van der Coelen D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16(4):426.","journal-title":"Arthritis Res Ther."},{"issue":"1\u20132","key":"602_CR20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","volume":"359","author":"SP Raychaudhuri","year":"2012","unstructured":"Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1\u20132):419\u201329.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"602_CR21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","volume":"64","author":"T Noordenbos","year":"2012","unstructured":"Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64(1):99\u2013109.","journal-title":"Arthritis Rheum"},{"key":"602_CR22","unstructured":"European Medicines Agency. Cosentyx: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 02 Jun 2016."},{"key":"602_CR23","unstructured":"US FDA. Cosentyx\u00ae (secukinumab) injection: US prescribing information. 2016. http:\/\/www.fda.gov . Accessed 02 Jun 2016."},{"issue":"4","key":"602_CR24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-015-0143-7","volume":"16","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2015;16(4):323\u201330.","journal-title":"Am J Clin Dermatol"},{"key":"602_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0598-8","author":"HA Blair","year":"2016","unstructured":"Blair HA, Dhillon S. Secukinumab: a review in ankylosing spondylitis. Drugs. 2016. doi: 10.1007\/s40265-016-0598-8 .","journal-title":"Drugs."},{"issue":"Suppl 2","key":"602_CR26","first-page":"11","volume":"23","author":"F Kolbinger","year":"2014","unstructured":"Kolbinger F, Bruin G, Valentin MA, et al. Treatment with secukinumab rapidly leads to positive proteomic and transcriptional changes in psoriatic skin [abstract no. P073]. Exp Dermatol. 2014;23(Suppl 2):11.","journal-title":"Exp Dermatol"},{"issue":"Suppl 1","key":"602_CR27","first-page":"S18","volume":"134","author":"G Bruin","year":"2014","unstructured":"Bruin G, Dragatin C, Aigner B, et al. The anti IL-17A IgG1 antibody distributes in dermal interstitial fluid as demonstrated by using dermal open flow microperfusion after a single 300 mg subcutaneous administration; assessment in healthy volunteers and patients with moderate-to-severe plaque psoriasis [abstract no. 106]. J Invest Dermatol. 2014;134(Suppl 1):S18.","journal-title":"J Invest Dermatol."},{"issue":"7","key":"602_CR28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/exd.12710","volume":"24","author":"K Reich","year":"2015","unstructured":"Reich K, Papp KA, Matheson RT, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015;24(7):529\u201335.","journal-title":"Exp Dermatol"},{"issue":"6","key":"602_CR29","first-page":"e140","volume":"171","author":"J Krueger","year":"2014","unstructured":"Krueger J, Wharton K, Fuentes-Duculan J, et al. Secukinumab reverses disease-defining psoriasis histopathology while retaining full T-cell activation potential [abstract no. P43]. Br J Dermatol. 2014;171(6):e140.","journal-title":"Br J Dermatol"},{"issue":"4 Suppl 1","key":"602_CR30","first-page":"AB212","volume":"68","author":"B Strober","year":"2013","unstructured":"Strober B, Guettner A, Sigurgeirsson B, et al. Secukinumab reduces C-reactive protein levels in patients with moderate to severe plaque psoriasis: result of a regimen-finding study [abstract no. P6395]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB212.","journal-title":"J Am Acad Dermatol."},{"issue":"8","key":"602_CR31","first-page":"821","volume":"14","author":"AB Gottlieb","year":"2015","unstructured":"Gottlieb AB, Langley RG, Philipp S, et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol. 2015;14(8):821\u201333.","journal-title":"J Drugs Dermatol"},{"issue":"Suppl 10","key":"602_CR32","first-page":"S233","volume":"66","author":"AB Gottlieb","year":"2014","unstructured":"Gottlieb AB, Mease P, McInnes IB, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial [abstract no. 537]. Arthritis Rheumatol. 2014;66(Suppl 10):S233.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"602_CR33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73(2):349\u201356.","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"602_CR34","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"602_CR35","doi-asserted-by":"crossref","first-page":"e4725","DOI":"10.1371\/journal.pone.0004725","volume":"4","author":"PAM Jansen","year":"2009","unstructured":"Jansen PAM, Rodijk-Olthuis D, Hollox EJ, et al. \u03b2-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One. 2009;4(3):e4725.","journal-title":"PLoS One"},{"issue":"4 Suppl 1","key":"602_CR36","first-page":"AB212","volume":"68","author":"U Mrowietz","year":"2013","unstructured":"Mrowietz U, Qureshi A, Escrig C, et al. Secukinumab treatment shows a neutral effect on the lipid profile of patients with moderate to severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled, phase II study [abstract no. P6871]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB212.","journal-title":"J Am Acad Dermatol."},{"issue":"4 Suppl 1","key":"602_CR37","first-page":"AB213","volume":"68","author":"S Philipp","year":"2013","unstructured":"Philipp S, Escrig C, Papavassilis C, et al. Secukinumab treatment shows a neutral impact on the lipid profile of patients with moderate to severe plaque psoriasis in a dose-ranging study [abstract no. P6508]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB213.","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"602_CR38","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/CVI.00386-12","volume":"19","author":"A Chioato","year":"2012","unstructured":"Chioato A, Noseda E, Stevens M, et al. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol. 2012;19(10):1597\u2013602.","journal-title":"Clin Vaccine Immunol"},{"key":"602_CR39","unstructured":"European Medicines Agency. Assessment report: Cosentyx (secukinumab). 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/003729\/WC500199573.pdf . Accessed 20 May 2016."},{"issue":"14","key":"602_CR40","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"9999","key":"602_CR41","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"9","key":"602_CR42","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","volume":"74","author":"MM Ward","year":"2015","unstructured":"Ward MM, Guthrie LC, Alba MI. Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis. 2015;74(9):1691\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"602_CR43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","volume":"70","author":"V Strand","year":"2010","unstructured":"Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70(2):121\u201345.","journal-title":"Drugs."},{"issue":"11","key":"602_CR44","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38(11):2461\u20135.","journal-title":"J Rheumatol"},{"key":"602_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0031-5","author":"P Mease","year":"2016","unstructured":"Mease P, McInnes IB. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol Ther. 2016. doi: 10.1007\/s40744-016-0031-5 .","journal-title":"Rheumatol Ther."},{"key":"602_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/art.39685","author":"D Heijde van der","year":"2016","unstructured":"van der Heijde D, Landew\u00e9 RB, Mease PJ, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol. 2016. doi: 10.1002\/art.39685 .","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 10","key":"602_CR47","first-page":"2576","volume":"67","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab provides sustained improvements in psoriatic arthritis: 2-year efficacy and safety results from a phase 3 randomized, double-blind, placebo-controlled trial [abstract no. 2148]. Arthritis Rheumatol. 2015;67(Suppl 10):2576\u20138.","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"602_CR48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 10","key":"602_CR49","first-page":"3433","volume":"67","author":"AB Gottlieb","year":"2015","unstructured":"Gottlieb AB, Thaci D, Blauvelt A, et al. Secukinumab improves skin symptoms and physical functioning compared with ustekinumab in patients with moderate to severe psoriasis with concomitant psoriatic arthritis: subanalysis of a randomized, double blind, parallel-group, active comparator-controlled phase 3b trial [abstract no. 2853]. Arthritis Rheumatol. 2015;67(Suppl 10):3433\u20134.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 2","key":"602_CR50","first-page":"870","volume":"74","author":"P Mease","year":"2015","unstructured":"Mease P, McInnes IB, Richards H, et al. Secukinumab safety and tolerability in patients with active psoriatic arthritis: pooled safety analysis of two phase 3, randomized, controlled trials (FUTURE 1 and FUTURE 2) [abstract no. SAT0579]. Ann Rheum Dis. 2015;74(Suppl 2):870\u20131.","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 93","key":"602_CR51","first-page":"S73","volume":"33","author":"L Gossec","year":"2015","unstructured":"Gossec L, Smolen JS. Treatment of psoriatic arthritis: management recommendations. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S73\u20137.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0602-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0602-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0602-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:35:51Z","timestamp":1718642151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0602-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,14]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0602-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,14]]}}}